Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
Andrew Blann University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UKThrombosis is the major common endpoint in most human diseases. In the coronary circulation, occlusive thrombi and/or the rupture of atherosclerotic plaque causes myocardial infarction, and in the...
Main Author: | Blann A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-08-01
|
Series: | Vascular Health and Risk Management |
Online Access: | http://www.dovepress.com/nonvitamin-k-antagonist-oral-anticoagulants-noacs-the-tide-continues-t-peer-reviewed-article-VHRM |
Similar Items
-
Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants
by: Yoshinari Morimoto, et al.
Published: (2016-03-01) -
Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?
by: Jong S. Kim
Published: (2019-09-01) -
The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
by: Jan Beyer-Westendorf, et al.
Published: (2021-07-01) -
Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
by: Anetta Undas, et al.
Published: (2019-12-01) -
The safety and efficacy of nonvitamin K antagonist oral anticoagulants in morbidly obese patients with atrial fibrillation: a meta-analysis
by: Sohil Elfar, et al.
Published: (2024-01-01)